Document:

QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10(i)  

 
  MEMBERSHIP INTEREST PLEDGE AGREEMENT    
  

        THIS MEMBERSHIP INTEREST PLEDGE AGREEMENT (this "Agreement") dated as of March 28, 2002 is given by
K2 INC., a Delaware corporation (the "Company"), and each subsidiary of the Company which from time to time becomes a party hereto (collectively,
together with the Company, the "Pledgors" and each individually a "Pledgor") in favor of BANK OF
AMERICA, N.A. ("Bank of America"), in its capacity as collateral agent (in such capacity, the "Collateral
Agent") under the Intercreditor Agreement referred to below, and the other Benefited Parties (as defined in such Intercreditor Agreement). 

W I T N E S S E T H:  

        WHEREAS, the Company, various financial institutions (the "Lenders") and Bank of America, as Administrative Agent
(in such capacity, the "Administrative Agent"), have entered into a Credit Agreement dated as of December 21, 1999 (as amended, restated or
otherwise modified from time to time, the "Credit Agreement"); 

        WHEREAS,
the Company is a party to separate Note Agreements dated as of October 15, 1992 (as amended, restated or otherwise modified from time to time, the
"1992 Note Agreements") with various purchasers (the "1992 Noteholders"); 

        WHEREAS,
the Company is a party to a Note Purchase Agreement dated as of December 1, 1999 (as amended, restated or otherwise modified from time to time, the
"1999 Note Agreement"; together with the 1992 Note Agreements, the "Note Agreements") with various
purchasers (the "1999 Noteholders"; together with the 1992 Noteholders, collectively the "Noteholders"); 

        WHEREAS,
each Pledgor other than the Company (if any) has guarantied all obligations of the Company under the Credit Agreement, the Note Agreements and certain other financing
arrangements; 

        WHEREAS,
pursuant to (i) the Continuing Guaranty dated August 19, 2000, (ii) the Amended and Restated Continuing Guaranty (Multicurrency) dated March 28, 2002
and (iii) the Continuing Guaranty (Multicurrency) dated July 31, 1998, the Company has guaranteed all of the obligations of K-2 Corporation, K2 Ski Sport + Mode
GmbH and Shakespeare Company (UK) Limited, respectively, under various financing arrangements made available to such entities by Bank of America and various subsidiaries and affiliates thereof; 

        WHEREAS,
pursuant to the Continuing Guaranty (Foreign Currency) dated October 29, 1998, the Company has guaranteed all of the obligations of K2 Japan Co. Ltd. under a
financing arrangement made available to such entity by Union Bank of California, N.A.; 

        WHEREAS,
pursuant to an Amended and Restated Intercreditor Agreement dated as of the date hereof (as amended, restated or otherwise modified from time to time, the
"Intercreditor Agreement"), the Administrative Agent, on behalf of itself and the Lenders, the Noteholders, various other parties from time to time
party thereto and the Collateral Agent have agreed that (i) the Benefited Obligations (as defined in the Intercreditor Agreement) shall be secured and guarantied pari
passu and (ii) Bank of America shall act as collateral agent for the Benefited Parties; and 

        WHEREAS,
the Benefited Obligations of each Pledgor are to be secured pursuant to this Agreement; 

        NOW,
THEREFORE, for and in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows: 

        1.    Definitions.    When used herein, (a) capitalized terms used but not defined in this Agreement have the
respective meanings assigned to such terms in the Intercreditor Agreement, (b) all terms defined in the Uniform Commercial Code as in effect on the date hereof in the State of California and 

 

used herein shall have the same definitions herein as specified therein, (c) references to agreements (including this Agreement) and other contractual instruments shall be deemed to include
all subsequent amendments and other modifications thereto, but only to the extent such amendments and other modifications are not prohibited by the terms of any Financing Agreement and (d) the
following terms
have the following meanings (such meanings to be applicable to both the singular and plural forms of such terms): 

        Administrative Agent—see the Recitals. 

        Agreement—see the Preamble. 

        Bank of America—see the Preamble. 

        Business Day means any day on which Bank of America is open for commercial banking business in Los Angeles, New York and Charlotte. 

        Collateral—see Section 2. 

        Collateral Agent—see the Preamble. 

        Company—see the Preamble. 

        Costs and Expenses means, with respect to any Pledgor, all reasonable out-of-pocket costs and expenses (including
reasonable attorneys' fees and legal expenses) incurred by the Collateral Agent in connection with (i) the execution, delivery and performance of this Agreement by such Pledgor,
(ii) protecting, preserving or maintaining any Collateral of such Pledgor, (iii) enforcing any rights of the Collateral Agent hereunder in respect of the Collateral of such Pledgor. 

        Credit Agreement—see the Recitals. 

        Default means the occurrence of any of the following events: (a) any Unmatured Event of Default under Section 8.01(f) or
(g) of the Credit Agreement, Section 6.1(i), (j) or (k) of the 1992 Note Agreements or Section 11(g) or (h) of the 1999 Note Agreement; (b) any Event
of Default; or (c) any warranty of any Pledgor herein is untrue or misleading in any material respect and, as a result thereof, the Collateral Agent's security interest for the benefit of the
Benefited Parties in any material portion of the Collateral is not perfected or the Collateral Agent's rights and remedies with respect to any material portion of the Collateral is materially impaired
or otherwise materially adversely affected. 

        Intercreditor Agreement—see the Recitals. 

        Lenders—see the Recitals. 

        Liabilities means, as to each Pledgor, all Benefited Obligations of such Pledgor. 

        LLC means a limited liability company in which any Pledgor is a member or otherwise has any equity interest. 

        LLC Agreement means the limited liability company agreement, operating agreement or similar basic agreement for any LLC, together with any
certificate of formation, articles of organization or similar constituent document, if any, required to be filed with the secretary of state, or equivalent office, in any applicable jurisdiction for
the legal and valid creation of such LLC (as amended, supplemented, restated or otherwise modified from time to time). 

        LLC Interests means all right, title and interest of any Pledgor in and to the following: each LLC in which such Pledgor has any interest,
all profits, income, surplus, compensation, return of capital, distributions and other disbursements and payments from any LLC to such Pledgor (including, without limitation, specific properties of
any LLC upon dissolution or otherwise), and all interests in any LLC now owned or hereafter acquired by such Pledgor as a result of exchange offers, direct investments, contributions or otherwise, and
all accounts, general intangibles and other rights to payment or 

2

 

reimbursement now existing or hereafter arising from loans, advances or other extensions of credit by such Pledgor from time to time to or for the account of any LLC, or from services rendered by
such Pledgor from time to time to or for the account of any LLC; but excluding any obligation or liability of such Pledgor with respect to any LLC or any duty of such Pledgor as a member of any LLC. 

        1992 Note Agreements—see the Recitals. 

        1992 Noteholders—see the Recitals. 

        1999 Note Agreement—see the Recitals. 

        1999 Noteholders—see the Recitals. 

        Note Agreements—see the Recitals. 

        Noteholders—see the Recitals. 

        Permitted Liens means (i) liens arising hereunder and (ii) inchoate tax and ERISA liens. 

        Pledged Property means all LLC Interests, all property received in exchange or substitution for any LLC Interest, all dividends,
distributions and other returns from any LLC Interest, all other property delivered by any Pledgor to the Collateral Agent for the purpose of pledge under this Agreement, and all proceeds of any of
the foregoing. 

        Pledgor—see the Preamble. 

        UCC means the Uniform Commercial Code as in effect from time to time in any applicable jurisdiction. 

        2.    Pledge.    As security for the payment of all Liabilities, each Pledgor hereby pledges and assigns to the
Collateral Agent for the benefit of the Benefited Parties, and grants to the Collateral Agent for the benefit of the Benefited Parties a continuing security interest in, all of the following: 

        A.    the
LLC Interests; 

        B.    all
cash and other property, real, personal or mixed, distributed or payable at any time or from time to time to such Pledgor from any LLC, as a distribution or otherwise
in complete or partial liquidation or otherwise, including, without limitation, such Pledgor's share of any revenues of any LLC derived from any contract; 

        C.    all
other Pledged Property; and 

        D.    all
products and proceeds of all of the foregoing. 

All
of the foregoing are herein collectively called the "Collateral". 

        3.    Delivery of Pledged Property.    (a) All certificates or instruments representing or evidencing any
Collateral, including those representing or evidencing any LLC Interest, shall be delivered to and held by or on behalf of the Collateral Agent pursuant hereto, shall be in suitable form for transfer
by delivery, and shall be accompanied by all necessary endorsements or instruments of transfer or assignment, duly executed in blank. 

        (b)  To
the extent any of the Collateral constitutes an "uncertificated security" (as defined in Section 8-102(a)(18) of the UCC), the applicable Pledgor
shall cause the issuer thereof to acknowledge to the Collateral Agent the registration on the books of such issuer of the pledge and security interest hereby created in the manner required by
Section 8-301(b) of the UCC. 

3

 

        4.    Warranties.    Each Pledgor warrants to the Collateral Agent for the benefit of each Benefited Party, as to
itself and its Collateral, that: 

        (a)    Ownership, No Liens, etc.    Such Pledgor is the legal and beneficial owner of, and has good title to (and has
full right and authority to pledge and assign) such Collateral, free and clear of all Liens, options or other charges or encumbrances, except Permitted Liens. No UCC financing statement covering any
of the Collateral is presently on file in any public office other than those in favor of the Collateral Agent for the benefit of the Benefited Parties. This Agreement creates a legal and valid
security interest in the Collateral which has been perfected as a first and prior Lien on the Collateral. No "control" as defined in Article 8 of the UCC has been given to any Person other than
the Collateral Agent. 

        (b)    LLC Interests.    The character of such Pledgor's interest in each LLC, and such Pledgor's percentage interest
in each LLC's profits as of the date hereof, are as set forth in Exhibit A. Such Pledgor has provided to the Collateral Agent true, correct and
complete copies of each LLC Agreement as in effect on the date hereof. 

        (c)    Authorization, Approval, etc.    Except for the filing of UCC financing statements, no authorization, approval
or other action by, and no notice to or filing with, any governmental authority or regulatory body or any other Person is required for (i) the pledge by such Pledgor of any Collateral pursuant
to this Agreement, (ii) the execution, delivery and performance of this Agreement by such Pledgor, (iii) the
exercise by the Collateral Agent of the voting or other rights provided for in this Agreement or (iv) except as may be required in connection with a disposition of any LLC Interest by laws
affecting the offering and sale of securities generally, the exercise by the Collateral Agent of remedies in respect of the Collateral pursuant to this Agreement. 

        (d)    Uncertificated Nature of LLC Interests.    No right, title or interest of such Pledgor in any LLC is
represented by a certificate or other instrument, except such certificates or instruments, if any, as have been delivered to the Collateral Agent and are held in its possession, together with transfer
documents as required in this Agreement (and such Pledgor covenants and agrees that any such certificates or instruments hereafter received by such Pledgor with respect to any of the Collateral will
be held in trust for the Collateral Agent for the benefit of the Benefited Parties and promptly delivered to the Collateral Agent). No Collateral is held in a securities account. No LLC is an
investment company and no LLC has expressly elected to have membership interests in such LLC treated as securities governed by Article 8 of the UCC. 

        (e)    Other.    (i) The assignment and pledge of the Collateral pursuant to this Agreement, together with the
filing of appropriate UCC financing statements, will create a valid perfected security interest in the Collateral in favor of the Collateral Agent; and (ii) all LLC Interests referred to on  Exhibit A are duly authorized, validly issued, fully paid and non-assessable. 

        5.    Covenants.    (a) No Pledgor will assign, pledge, grant any security interest in or, except to the extent
permitted by all of the Financing Agreements, sell or otherwise transfer any of the Collateral of such Pledgor or grant any option, warrant or other right to purchase the Collateral of such Pledgor
(except in favor of the Collateral Agent and the Benefited Parties hereunder). Each Pledgor will warrant and defend the right and title herein granted unto the Collateral Agent in and to the
Collateral (and all right, title and interest represented by the Collateral) against the claims and demands of all other Persons. Each Pledgor agrees that at any time, and from time to time, at the
expense of such Pledgor, such Pledgor will promptly execute and deliver all further instruments, and take all further action, that may be necessary or desirable, or that the Collateral Agent may
reasonably request, in order to perfect and protect any security interest granted or purported to be granted hereby or to enable the Collateral Agent to exercise and enforce its rights and remedies
hereunder with respect to any Collateral. Each Pledgor shall provide the Collateral Agent with copies of all written information received from any securities intermediary of such Pledgor with respect
to any Collateral. 

4

 

        (b)  Each
Pledgor agrees that it will: (i) execute such additional UCC financing statements and other documents (and pay the cost of filing or recording the same in
all public offices reasonably deemed necessary or appropriate by the Collateral Agent) and do such other acts and things, all as the Collateral Agent may from time to time reasonably request, as are
necessary to establish and maintain a valid, perfected pledge (including, without limitation, a perfected pledge by means of control) of, and security interest in, the Collateral (free of all other
Liens other than Permitted Liens) to secure the payment and performance of the Liabilities; (ii) not make any change in the name or jurisdiction of organization of such Pledgor without giving
the Collateral Agent at least 30 days' prior written notice
thereof; (iii) furnish the Collateral Agent such information concerning the Collateral as the Collateral Agent may from time to time reasonably request; (iv) provide the Collateral
Agent, not less than 10 days after entering into same, a copy of each LLC Agreement and any amendment or supplement to, or modification or waiver of, any term or provision of any LLC Agreement;
(v) upon learning of the occurrence of any Default, promptly upon request of the Collateral Agent transfer any LLC Interest constituting Collateral into the name of any nominee or
sub-agent designated by the Collateral Agent; and (vi) upon learning of the occurrence of any event which could reasonably be expected to cause termination and/or dissolution of any
LLC, notify the Collateral Agent in writing thereof. 

        6.    Holding in Name of Collateral Agent, etc.    The Collateral Agent may from time to time after the occurrence and
during the continuance of a Default, without notice to any Pledgor, take all or any of the following actions: (a) transfer all or any part of the Collateral into the name of the Collateral
Agent or any nominee or sub-agent for the Collateral Agent, with or without disclosing that such Collateral is subject to the lien and security interest hereunder; (b) appoint one
or more sub-agents or nominees for the purpose of retaining physical possession of the Collateral; (c) notify the parties obligated on any of the Collateral to make payment to the
Collateral Agent of any amounts due or to become due thereunder; (d) endorse any checks, drafts or other writings in the name of any Pledgor to allow collection of the Collateral;
(e) enforce collection of any of the Collateral by suit or otherwise, and surrender, release or exchange all or any part thereof, or compromise or renew for any period (whether or not longer
than the original period) any obligations of any nature of any party with respect thereto; and (f) take control of any proceeds of the Collateral. 

        7.    Voting Rights, Dividends, etc.    (a) So long as the Collateral Agent has not given the notice referred
to in paragraph (b) below: 

        A.    Each
Pledgor shall be entitled to exercise any and all voting or consensual rights and powers with respect to any LLC Interest or other Pledged Property of such Pledgor
or any part thereof for any purpose; provided that each Pledgor agrees that it will not exercise any such right or power in any manner which would have
a material adverse effect on the Collateral Agent's rights with respect to any material portion of the Collateral. 

        B.    Each
Pledgor shall be entitled to receive and retain any and all lawful dividends or other distributions payable in respect of the Collateral of such Pledgor which are
paid in cash by any LLC if such dividends or distributions are permitted by each of the Financing Agreements. 

        C.    The
Collateral Agent shall execute and deliver, or cause to be executed and delivered, to the Pledgors, all such proxies, powers of attorney, dividend orders and other
instruments as any Pledgor may request for the purpose of enabling such Pledgor to exercise the rights and powers which it is entitled to exercise pursuant to  clause (A) above and to receive the
dividends and distributions which it is authorized to retain pursuant to  clause (B) above. 

        (b)  Upon
written notice to the Company from the Collateral Agent during the existence of a Default, and so long as the same shall be continuing, all rights and powers which
the Pledgors are entitled to exercise pursuant to Section 7(a)(A) hereof, and all rights of the Pledgors to receive and retain dividends and
distributions pursuant to Section 7(a)(B) hereof, shall forthwith cease, and all such rights and powers shall thereupon become vested in the
Collateral Agent which shall have, during the 

5

 

continuance of such Default, the sole and exclusive authority to exercise such rights and powers and to receive such dividends and distributions. Any and all money and other property paid over to or
received by the Collateral Agent pursuant to this paragraph (b) shall be retained by the Collateral Agent as additional Collateral hereunder and
applied in accordance with the provisions hereof. 

        8.    Additional LLC Interests.    No Pledgor will (a) permit the issuance of (i) any additional limited
liability company interests or any class of limited liability company interests of any LLC, (ii) any securities convertible into, or exchangeable for, any such limited liability company
interests, or (iii) any warrants, options, contracts or other commitments entitling any Person to purchase or otherwise acquire any such limited liability company interests or (b) enter
into any agreement creating, or otherwise permit to exist, any restriction or condition upon the transfer, voting or control of any interest in any LLC. 

        9.    Remedies.    Whenever a Default exists, the Collateral Agent may exercise from time to time any rights and
remedies available to it under the UCC or otherwise available to it. Without limiting the foregoing, whenever a Default exists, the Collateral Agent (a) may, to the fullest extent permitted by
applicable law, without notice, advertisement, hearing or process of law of any kind, (i) sell any or all of the Collateral of any Pledgor, free of all rights and claims of such Pledgor therein
and thereto, at any public or private sale or brokers' board, and (ii) bid for and purchase any or all of the Collateral at any such public sale and (b) shall have the right, for and in
the name, place and stead of such Pledgor, to execute endorsements, assignments, stock powers and other instruments of conveyance or transfer with respect to all or any of the Collateral. Each Pledgor
hereby expressly waives, to the fullest extent permitted by applicable law, any and all notices, advertisements, hearings or process of law in connection with the exercise by the Collateral Agent of
any of its rights and remedies during the continuance of a Default. Any notification of intended disposition of any of the Collateral shall be deemed reasonably and properly given if given at least 10
Business Days before such disposition. Any proceeds of any of the Collateral may be applied by the Collateral Agent to the payment of Costs and Expenses, and any balance of such proceeds may be
applied by the Collateral Agent toward the payment of the Liabilities in accordance with the terms of the Intercreditor Agreement (and, after payment in full of all Liabilities, any excess shall be
delivered to the applicable Pledgor or as a court of competent jurisdiction shall direct). 

        The
Collateral Agent is hereby authorized to comply with any limitation or restriction in connection with any sale of Collateral as it may be advised by counsel is necessary in order to
(a) avoid any violation of applicable law (including, without limitation, compliance with such procedures as may restrict the number of prospective bidders and purchasers and/or further
restrict such prospective bidders or purchasers to Persons who will represent and agree that they are purchasing for their own account for investment and not with a view to the distribution or resale
of such Collateral) or (b) obtain any required approval of the sale or of the purchase by any governmental or regulatory authority or official, and each Pledgor agrees that such compliance
shall not result in such sale being considered or deemed not to have been made in a commercially reasonable manner and that the Collateral Agent
shall not be liable or accountable to any Pledgor for any discount allowed by reason of the fact that such Collateral is sold in compliance with any such limitation or restriction. 

        Each
Pledgor hereby appoints the Collateral Agent as the attorney-in-fact for such Pledgor for the purpose of carrying out the provisions of this Agreement and
taking any action and executing or completing any instruments which the Collateral Agent may deem reasonably necessary or advisable to accomplish the purposes hereof, which appointment as
attorney-in-fact is irrevocable and coupled with an interest; provided that the Collateral Agent shall not exercise its rights
as such attorney-in-fact unless a Default exists. 

        This
Agreement shall remain in full force and effect until the earlier to occur of (a) the payment in full in cash of all Liabilities and the termination of all commitments to
create Liabilities and (b) the 

6

 

Collateral Release Date. Upon any such termination, the Collateral Agent will, upon any Pledgor's request and at such Pledgor's sole expense, (i) deliver to such Pledgor, without any
representation, warranty or recourse of any kind whatsoever, all of such Pledgor's Collateral held by the Collateral Agent hereunder as shall not have been sold or otherwise applied pursuant to the
terms hereof, and (ii) execute and deliver to such Pledgor such documents as such Pledgor shall reasonably request to evidence such termination and the release of any security interest granted
hereby. If the Collateral Agent reasonably determines that it is permitted to release any Collateral in accordance with Section 3(f) or 9(g) of the Intercreditor Agreement, then the Collateral
Agent will, upon the applicable Pledgor's request and at such Pledgor's sole expense, execute and deliver such releases as may be necessary to terminate the Collateral Agent's security interest (for
the benefit of the Benefited Parties), in such Collateral. 

        10.    Acknowledgment of Control.    By its signature below, each Pledgor (i) acknowledges that it has not
previously granted "control" over the Collateral of such Pledgor to any other Person and (ii) agrees that it will not grant any Person other than the Collateral Agent "control" over any
Collateral. 

        11.    Restrictions on Pledge.    The parties hereto acknowledge that K2 Finance Company, LLC (the "Receivables
Seller"), various affiliates of the Receivables Seller and certain of its subsidiaries have entered into a structured receivables financing transaction with Redwood Receivables Corporation ("Redwood")
and General Electric Capital Corporation (the "Redwood Agent") pursuant to a Receivables Purchase and Servicing Agreement (the "Purchase Agreement"). To induce Redwood and the Redwood Agent to permit
the pledge of the membership interests of the Receivables Seller (the "Pledged Collateral"), the parties hereto agree to the following limitations. Capitalized terms used in this Section 11
shall have the meanings ascribed to such terms in the Purchase Agreement. 

        (a)  Anything
herein or in the Parent Revolver, 1992 Note Agreement or 1994 Note Agreement to the contrary notwithstanding: 

          (i)  Until
91 days after the date on which the Purchaser Interest and all other amounts owed under the Related Documents have been paid in full in cash in accordance
with the terms of the Related Documents, the Collateral Agent, for itself and as agent for the Benefited Parties, agrees that, upon exercising its rights with respect to the Pledged Collateral, it
will not take any action with respect thereto which is adverse to the interests of Redwood and/or the Redwood Agent, including, without limitation, (A) causing the Receivables Seller to violate
or breach any term or provision in any Related Documents, (B) making any dividends or distributions on the Pledged Collateral, (C) amending or altering any of the Receivables Seller's
organizational documents, or (D) causing the Receivables Seller to incur any debt, other than, in each case, as may be allowed in the Related Documents;  provided that any prepayment or termination
of the Purchase Agreement in accordance with the terms of the Related Documents shall not be deemed adverse
to the interests of Redwood and/or the Redwood Agent; 

        (ii)  If
the Collateral Agent or any other Benefited Party receives any payments or funds relating to the Receivables (the "Receivables Assets") prior to the date on which
the Purchaser Interest and all other amounts owed under the Related Documents have been paid in full in cash in accordance with the terms of the Related Documents, such Person shall hold such payments
or funds in trust for the benefit of the Redwood Agent, and shall promptly transfer such payments or funds to the Redwood Agent; 

        (iii)  The
provisions of this Section 11 shall continue to be effective or be reinstated, as the case may be, if at any
time any payment of the Purchaser Interest or any other amount owed under the Related Documents is rescinded or must otherwise be returned by the Redwood Agent or the Purchasers upon the insolvency,
bankruptcy or reorganization of the Receivables Seller, SPC or otherwise, all as though such payment had not been made; and 

7

 

        (iv)  Prior
to the date on which the Purchaser Interest and all other amounts owed under the Related Documents have been indefeasibly paid in full in cash in accordance with
the terms of the Related Documents, neither the Collateral Agent nor any other Benefited Party shall object to or contest in any administrative, legal or equitable action or proceeding (including,
without limitation, any insolvency, bankruptcy, receivership, liquidation, reorganization, winding up, readjustment, composition or other similar proceeding relating to Parent Guarantor, any
Originator, SPC or the Receivables Seller or their respective property) or object to or contest in any other manner (A) the interests of the Receivables Seller and its successors and assigns in
any of the Receivables Assets transferred by each Originator or its affiliates to the Receivables Seller pursuant to the Related Documents and/or (B) the interests of the Redwood Agent or the
Purchasers in the Receivables Assets. Neither the Collateral Agent nor any other Benefited Party shall object to or contest in any manner the receipt of any payment by the Redwood Agent and/or the
Purchasers with respect to the Receivables Assets for the satisfaction of the Purchaser Interest. 

        (b)  The
Redwood Agent and Redwood shall be third-party beneficiaries with respect to this Section 11. 

        (c)  So
long as the Purchaser Interest and all other amounts owed under the Related Documents have not been indefeasibly paid in full in cash in accordance with the terms of
the Related Documents, this Section 11 shall not be amended, modified or supplemented without the prior written consent of the Redwood Agent,
which consent shall not be unreasonably withheld, and the provisions of this Section 11 shall be contained in any agreement that amends and
restates this Agreement. The Collateral Agent and, by accepting the benefits hereof, each of the other Benefited Parties agree that no such party shall enter into any additional agreement that would
be contrary to the provisions of this Section 11. 

        (d)  Until
the Purchaser Interest and all other amounts owed under the Related Documents have been indefeasibly paid in full in cash in accordance with the terms of the
Related Documents, the Collateral Agent shall not sell, transfer or otherwise assign it rights in the Pledged Collateral unless such assignee agrees in writing to be bound by this Section and a copy
of such writing has been delivered to the Redwood Agent. 

        13.    General.    The Collateral Agent shall be deemed to have exercised reasonable care in the custody and
preservation of the Collateral if it takes such action for that purpose as the applicable Pledgor shall request in writing, but failure of the Collateral Agent to comply with any such request shall
not of itself be deemed a failure to exercise reasonable care, and no failure of the Collateral Agent to preserve or protect any rights with respect to the Collateral against prior parties, or to do
any act with respect to preservation of the Collateral not so requested by any Pledgor, shall be deemed a failure to exercise reasonable care in the custody or preservation of any Collateral. 

        No
delay on the part of the Collateral Agent in exercising any right, power or remedy shall operate as a waiver thereof, and no single or partial exercise of any such right, power or
remedy shall preclude any other or further exercise thereof, or the exercise of any other right, power or remedy. No amendment, modification or waiver of, or consent with respect to, any provision of
this Agreement shall be effective unless the same shall be in writing and signed and delivered by the Collateral Agent, and then such amendment, modification, waiver or consent shall be effective only
in the specific instance and for the specific purpose for which given. 

        All
obligations of each Pledgor and all rights, powers and remedies of the Collateral Agent and the Benefited Parties expressed herein are in addition to all other rights, powers and
remedies possessed by them, including, without limitation, those provided by applicable law or in any other written instrument or agreement relating to any of the Liabilities or any security therefor. 

8

 

        This
Agreement shall be construed in accordance with and governed by the internal laws of the State of California. Wherever possible each provision of this Agreement shall be interpreted
in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective to the
extent of such
prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. 

        This
Agreement shall be binding upon each Pledgor and the Collateral Agent and their respective successors and assigns, and shall inure to the benefit of each Pledgor and the Collateral
Agent and the successors and assigns of the Collateral Agent. 

        This
Agreement may be executed in any number of counterparts and by the different parties hereto on separate counterparts, and each such counterpart shall be deemed an original but all
such counterparts shall together constitute but one and the same Agreement. At any time after the date of this Agreement, one or more additional Persons may become parties hereto by executing and
delivering to the Collateral Agent a counterpart of this Agreement (together with a supplement to Exhibit A hereto). Immediately upon such
execution and delivery (and without any further action), each such additional Person will become a party to, and will be bound by all of the terms of, this Agreement. 

        ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY OTHER FINANCING AGREEMENT, SHALL BE BROUGHT AND MAINTAINED
EXCLUSIVELY IN THE COURTS OF THE STATE OF CALIFORNIA OR IN THE UNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA; PROVIDED THAT ANY
SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT THE COLLATERAL AGENT'S OPTION, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE
FOUND. EACH PLEDGOR HEREBY EXPRESSLY AND IRREVOCABLY SUBMITS TO THE JURISDICTION OF THE COURTS OF THE STATE OF CALIFORNIA AND OF THE UNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA
FOR THE PURPOSE OF ANY SUCH LITIGATION AS SET FORTH ABOVE. EACH PLEDGOR FURTHER IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, TO THE ADDRESS OF SUCH PLEDGOR SET
FORTH BELOW ITS SIGNATURE HERETO (OR SUCH OTHER ADDRESS AS IT SHALL HAVE SPECIFIED IN WRITING TO THE COLLATERAL AGENT AS ITS ADDRESS FOR NOTICES HEREUNDER), OR BY PERSONAL SERVICE WITHIN OR WITHOUT
THE STATE OF CALIFORNIA. EACH PLEDGOR HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY
SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

        EACH PLEDGOR, THE COLLATERAL AGENT AND (BY ACCEPTING THE BENEFITS HEREOF) EACH OTHER BENEFITED PARTY HEREBY WAIVE ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION OR
PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS UNDER THIS AGREEMENT, ANY OTHER FINANCING AGREEMENT AND ANY AMENDMENT, INSTRUMENT, DOCUMENT OR AGREEMENT DELIVERED OR WHICH MAY IN THE FUTURE BE DELIVERED IN
CONNECTION HEREWITH OR THEREWITH OR ARISING FROM ANY FINANCING RELATIONSHIP EXISTING IN CONNECTION WITH ANY OF THE FOREGOING, AND AGREE THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT
AND NOT BEFORE A JURY.

9

   
        IN WITNESS WHEREOF, this Agreement has been duly executed and delivered as of the day and year first written above. 

	 	 	K2 INC.
	

 	
 	

By:	

 
	 	 	 	

	 	 	Name Printed:	 
	 	 	 	

	 	 	Title:	 
	 	 	 	

	

 	
 	

Address:
	

 	
 	

4900 South Eastern Avenue

Los Angeles, CA 90040

Attention: John Rangel

Facsimile: (323) 724-0470
	

 	
 	

STEARNS INC.

SHAKESPEARE COMPANY, LLC

K-2 CORPORATION
	

 	
 	

By:	

 
	 	 	 	

	 	 	Name Printed:	 
	 	 	 	

	 	 	Title:	 
	 	 	 	

	

 	
 	

Address:
	

 	
 	

4900 South Eastern Avenue

Los Angeles, CA 90040

Attention: John Rangel

Facsimile: (323) 724-0470

S-1

 

	 	 	BANK OF AMERICA, N.A., as Collateral Agent
	

 	
 	

By:	

 
	 	 	 	

	 	 	Name Printed:	 
	 	 	 	

	 	 	Title:	 
	 	 	 	

	

 	
 	

Address:
	

 	
 	

Agency Management

CA9-706-11-03

555 S. Flower Street, 11th Floor

Los Angeles, CA 90071

Attention: Gina Meador

Facsimile: (213) 228-2299

S-2

 

	 	 	Additional signature page for the Membership Interest Pledge Agreement dated as of March 28, 2002 issued by K2 Inc. (the "Company") and various subsidiaries of the Company.
	

 	
 	

The undersigned is executing a counterpart hereof for purposes of becoming a party hereto (and attached to this signature page is a supplement to Exhibit A of the Membership Interest Pledge Agreement setting forth all relevant information with
respect to the undersigned).
	

 	
 	

[NAME OF SUBSIDIARY]
	

 	
 	

By:	

 
	 	 	 	

	 	 	Name:	 
	 	 	 	

	 	 	Title:	 
	 	 	 	

	

 	
 	

Address:	

 
	 	 	 	

	 	 	 	

	 	 	 	

S-3

EXHIBIT A

TO MEMBERSHIP INTEREST PLEDGE AGREEMENT  

DESCRIPTION OF LLC INTERESTS and LLC AGREEMENTS  

The
Company is pledging the following: 

	1.
	100%
of the membership interests of Shakespeare Company, LLC owned by it pursuant to the Limited Liability Company Agreement dated as of March 1, 2001

	2.
	100%
of the membership interests of Shakespeare Conductive Fibers, LLC owned by it pursuant to the Limited Liability Company Agreement dated as of December 14, 2000 

Shakespeare
Company, LLC, a Delaware limited liability company, K-2 Corporation, an Indiana corporation, and Stearns Inc., a Minnesota corporation, all wholly-owned subsidiaries of
the Company, are pledging the following: 

        1.    100%
of the membership interests of K2 Finance Company, LLC owned by them pursuant to the Limited Liability Company Agreement of K2 Finance Company, LLC dated as of
March 26, 2002. 

QuickLinks

MEMBERSHIP INTEREST PLEDGE AGREEMENT<Page>

CONFIDENTIAL TREATMENT REQUESTED                                  EXHIBIT 10.68

CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
IS REQUESTED IS OMITTED AND IS NOTED WITH "[CONFIDENTIAL TREATMENT REQUESTED]."
AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                          THIRD AMENDMENT TO AGREEMENT

     THIS THIRD AMENDMENT TO AGREEMENT ("Third Amendment") is made and effective
as of this 12th day of November, 2001, by and between MDS (CANADA) INC., MDS
NORDION division, successor to MDS NORDION INC. ("Nordion"), and IDEC
PHARMACEUTICALS CORPORATION ("IDEC").

WHEREAS:

     A. Nordion and IDEC are parties to that certain Agreement dated May 14,
1999, whereby Nordion agreed to manufacture and supply Isotope for use with
IDEC's Labelled Drug ("Isotope Agreement").

     B. The Isotope Agreement was subsequently amended by a letter agreement
between the parties dated January 25, 2000 (`First Amendment"), a letter
agreement between the parties dated March 21, 2000 relating to Isotope dose size
("Isotope Dose Size Letter") and a Letter Agreement between the parties dated
March 22, 2001 ("Second Amendment"). The Isotope Agreement, as amended by the
First Amendment, Isotope Dose Size Letter and Second Amendment are collectively
referred to herein as the "Agreement."

     C. Nordion and IDEC desire to further amend the Agreement as set forth in
this Third Amendment.

     D. Unless otherwise defined herein, capitalized items as used herein shall
have the meanings as given thereto in the Agreement.

NOW THEREFORE, in consideration of the mutual covenants and agreements herein
contained, and subject to the terms and conditions hereinafter set out, the
parties agree as follows:

1.   INCREASED DOSE SIZE, PRICE AND REPORTING.

     1.1  Section 6.2 of the Agreement relating to production planning for
          Clinical Trial and Pre-Commercial Phase supply is amended to provide
          that Isotope may be shipped in as many as [CONFIDENTIAL TREATMENT
          REQUESTED] sizes to be discussed by the parties and approved by IDEC,
          however it is anticipated that a dose size of [CONFIDENTIAL TREATMENT
          REQUESTED] per vial at Calibration will be required.

     1.2  During the Commercial Phase the dose size shall be [CONFIDENTIAL
          TREATMENT REQUESTED] at Calibration.

                                        1
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

     1.3  Subject to Section 7.6 of the Agreement, the maximum purchase price
          for Isotope during the Commercial Phase shall be [CONFIDENTIAL
          TREATMENT REQUESTED] per dose. The purchase price includes all
          shipping, insurance and customs charges ("Charges") currently
          estimated to average [CONFIDENTIAL TREATMENT REQUESTED] per dose. The
          parties agree to adjust the minimum purchase price on an annual basis
          commencing [CONFIDENTIAL TREATMENT REQUESTED] to reflect any increase
          or decrease in the average cost of such Charges incurred by Nordion
          during the prior year.

     1.4  Upon commencement of the Commercial Phase and notwithstanding the
          notice required set out in Section 7.1(ii) of the Agreement, Nordion
          shall [CONFIDENTIAL TREATMENT REQUESTED] for use with IDEC's
          Monoclonal Antibody. Title in and to Isotope and risk of loss shall
          [CONFIDENTIAL TREATMENT REQUESTED]. For the purposes of certainty,
          Nordion may refuse to supply Isotope [CONFIDENTIAL TREATMENT
          REQUESTED]. Such refusal to supply shall not affect IDEC's minimum
          purchase commitment under the Agreement.

     1.5  From time to time during the Commercial Phase, but in any event not
          less than [CONFIDENTIAL TREATMENT REQUESTED], the parties shall meet
          to discuss Isotope vial fill optimization. If the parties determine in
          good faith that the amount of Isotope shipped per dose can be reduced
          without impacting the [CONFIDENTIAL TREATMENT REQUESTED] at
          Calibration dose size requirement or that a smaller dose size meets
          Labelled Drug administration requirements, the purchase price shall,
          subject to Section 7.6 of the Agreement, be based on a maximum price
          of [CONFIDENTIAL TREATMENT REQUESTED] per [CONFIDENTIAL TREATMENT
          REQUESTED] at Calibration, plus Charges.

     1.6  Once construction of the New Faci1ity is comp1ete and it is capable of
          supplying Isotope the readiness fee in Section 6.5 of the Agreement
          shall be increased to [CONFIDENTIAL TREATMENT REQUESTED] and
          [CONFIDENTIAL TREATMENT REQUESTED], shall not [CONFIDENTIAL TREATMENT
          REQUESTED]. In the event Nordion is sourcing radiochemica1 grade
          yttrium-90 in house, for the purposes or Section 6.5 of the Agreement,
          the [CONFIDENTIAL TREATMENT REQUESTED] shall be [CONFIDENTIAL
          TREATMENT REQUESTED].

     1.7  Nordion agrees that it shall provide or otherwise cause to be provided
          to IDEC the following reports on a per customer basis by e-mail or
          fax:

          (i)    confirmation, within 1 full business day of receipt of Isotope
                 orders, setting out the total number of orders placed in a
                 particular day from customers including a summary of declined
                 orders for reasons including

                                        2
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                 but not limited to customer's failure to have a radioactive
                 materials license;

          (ii)   advance shipping notice including information with respect to
                 planned Isotope shipping dates, customer address and quantities
                 ordered, provided on the day of shipment;

          (iii)  weekly summary exception reports provided on Friday of each
                 week setting out missed shipments (arrival after 12 noon in
                 customer's time zone), product complaints and replaced doses in
                 such week, if applicable; and

          (iv)   any and all distribution or other reports required by the FDA.

          For the purpose of the audit rights set out in Section 11.1 of the
          Agreement, IDEC'S right of audit shall be extended for the purpose of
          verification of fulfillment of Nordion's obligations set forth in this
          Section 1.7. Any auditor engaged pursuant to Section 11.1 of the
          Agreement shall prior to carrying out such audit enter into a
          confidentiality agreement reasonably acceptable to Nordion and IDEC
          for the purpose of protecting the confidential information of each
          respective party.

2.   TERMINATION RIGHTS.

     2.1  IDEC agrees that it shall not exercise its termination rights set
          forth in Section 17.3 of the Agreement and such termination right,
          except as set forth below, shall be suspended until such time as
          [CONFIDENTIAL TREATMENT REQUESTED] reach [CONFIDENTIAL TREATMENT
          REQUESTED] in the aggregate, including [CONFIDENTIAL TREATMENT
          REQUESTED] under the Agreement or to third parties during the period
          in which the Agreement remains in force [CONFIDENTIAL TREATMENT
          REQUESTED]. Nordion shall notify IDEC as soon as Nordion becomes aware
          that the [CONFIDENTIAL TREATMENT REQUESTED] has been reached.

     2.2  Nordion agrees that it shall not exercise its termination rights set
          forth in Section 17.3 of the Agreement and such termination rights
          shall be suspended until Nordion has had the capability to
          commercially supply Isotope from the KRMF Facility (as such term is
          defined in Section 4.1 of this Third Amendment below) for five years.
          This five-year period includes the 24-month notice requirement set
          forth in Section 17.3 of the Agreement. For purposes of this Section
          2.2 and elsewhere in this Third Amendment, Nordion shall be deemed to
          be capable of commercially supplying Isotope from the KRMF Facility as
          of [CONFIDENTIAL TREATMENT REQUESTED]. Nordion shall timely notify
          IDEC of such date.

     2.3  Notwithstanding Section 2.1 of this Third Amendment, IDEC may exercise
          its termination right pursuant to Section 17.3 of the Agreement at any
          time prior to the later of (i) BLA approval of the Labelled Drug or
          (ii) the date Nordion is

                                        3
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

          capable of commercially supplying Isotope from the KRMF Facility. In
          the event that IDEC exercises its right to terminate the Agreement
          pursuant to this Section 2.3, or Nordion or IDEC terminate the
          Agreement pursuant to Section 17.6 of the Agreement, IDEC,
          [CONFIDENTIAL TREATMENT REQUESTED], shall pay Nordion an amount equal
          to the sum of:

                 (a)  the lesser of (i) [CONFIDENTIAL TREATMENT REQUESTED] minus
                 [CONFIDENTIAL TREATMENT REQUESTED] under the Agreement from the
                 sale of Isotope and/or Yttriurn-90 manufactured by the
                 [CONFIDENTIAL TREATMENT REQUESTED] up to the effective date of
                 termination or (ii) Nordion's [CONFIDENTIAL TREATMENT
                 REQUESTED] associated with the establishment of the
                 [CONFIDENTIAL TREATMENT REQUESTED] to the date of the
                 termination notice minus [CONFIDENTIAL TREATMENT REQUESTED]
                 under the Agreement from the sale of Isotope and/or Yttrium-90
                 manufactured by the [CONFIDENTIAL TREATMENT REQUESTED] up to
                 the effective date of termination, plus

                 (b)  an amount equal to [CONFIDENTIAL TREATMENT REQUESTED],
                 provided, however, in no event shall such amount exceed
                 [CONFIDENTIAL TREATMENT REQUESTED], plus

                 (c)  any amounts otherwise payable pursuant to Section 17.3 of
                 the Agreement.

          [CONFIDENTIAL TREATMENT REQUESTED]

          Upon receipt of notice of termination of the Agreement pursuant to
          this Section 2.3, Nordion may cease all work on the KRMF Facility.

     2.4  In addition to IDEC's rights set forth in Section 2.3 of this Third
          Amendment, and notwithstanding Section 2.1 above, IDEC may terminate
          the Agreement with respect to [CONFIDENTIAL TREATMENT REQUESTED], at
          any time prior to the later of (i) BLA approval of the Labelled Drug,
          or (ii) the date Nordion is capable of commercially supplying Isotope
          from the KRMF Facility. In the event that IDEC exercises its right
          under this Section 2.4, IDEC, in order to [CONFIDENTIAL TREATMENT
          REQUESTED], provided, however, in no event shall such amount exceed
          [CONFIDENTIAL TREATMENT REQUESTED].

     2.5  Subject to Section 7.6 of the Agreement, Nordion agrees that IDEC may
          at any time within [CONFIDENTIAL TREATMENT REQUESTED] following the
          effective date of termination pursuant to Sections 2.3, 2.4, 5.11 and
          5.13 of this Third Amendment reinstate the Agreement as amended by
          this Third Amendment upon [CONFIDENTIAL TREATMENT REQUESTED] prior
          written notice to Nordion, and provided the parties agree on an amount
          to be secured in Escrow to

                                       4
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

          be negotiated in good faith for [CONFIDENTIAL TREATMENT REQUESTED]
          after the date of termination, as the case may be. It is acknowledged
          and agreed that the Agreement, as reinstated, shall [CONFIDENTIAL
          TREATMENT REQUESTED]. Notwithstanding anything to the contrary set
          forth in this Section 2.5, in the event Nordion advises IDEC in
          writing during the [CONFIDENTIAL TREATMENT REQUESTED] reinstatement
          period that it has initiated negotiations with a third party regarding
          use of [CONFIDENTIAL TREATMENT REQUESTED]. IDEC shall have
          [CONFIDENTIAL TREATMENT REQUESTED] from the date of such notification
          to elect with respect to such facility to reinstate the Agreement in
          accordance with this Section 2.5 or waive such right of reinstatement.
          IDEC's failure to respond within the forgoing [CONFIDENTIAL TREATMENT
          REQUESTED] period shall be deemed a waiver of IDEC's right of
          reinstatement. In the event IDEC waives such right of reinstatement
          and Nordion's negotiations with such third party fail to result in
          agreement to utilize the applicable facility, Nordion shall promptly
          notify IDEC and IDEC shall again have thc right of reinstatement set
          forth in this Section 2.5 until expiration of the original
          [CONFIDENTIAL TREATMENT REQUESTED] reinstatement period, subject to
          Nordion's continuing right to initiate negotiations with a third party
          and to require IDEC to elect to reinstate the Agreement or waive such
          right within [CONFIDENTIAL TREATMENT REQUESTED].

     2.6  This Article 2 of this Third Amendment hereby supersedes Article 2 of
          the Second Amendment. In the event IDEC exercises the termination
          rights set forth in Section 2.4 of this Third Amendment, Article 2 of
          the Second Amendment shall be reinstated and Sections 2.1 - 2.5, 3.1 -
          3.4, 4.1 - 4.4, 51 - 5.13 and 7.4 of this Third Amendment shall no
          longer be applicable, provided IDEC has met all of its obligations set
          out in Section 2.4 above.

3.   MINIMUM PURCHASE COMMITMENT.

     3.1  The [CONFIDENTIAL TREATMENT REQUESTED] Commercial Phase minimum
          purchase commitment set forth in Section 7.1(i) the Agreement is
          hereby amended and replaced with the following Commercial Phase
          minimum purchase commitment.

          ----------------------------------------------------------------------
                                    MINIMUM PURCHASE COMMITMENT
          ----------------------------------------------------------------------
          [CONFIDENTIAL TREATMENT               Gross Revenue excluding Charges
              REQUESTED] Period                 ($ US) from the sale of Isotope
          ----------------------------------- ----------------------------------
          Commencement of Commercial Phase
           through the date
          [CONFIDENTIAL TREATMENT REQUESTED]  [CONFIDENTIAL TREATMENT REQUESTED]
          following the commencement of the
           Commercial Phase
          [CONFIDENTIAL TREATMENT REQUESTED]
          --------------------------- ------- ----------------------------------
          [CONFIDENTIAL TREATMENT REQUESTED]  [CONFIDENTIAL TREATMENT REQUESTED]
          --------------------------- ------- ----------------------------------
          [CONFIDENTIAL TREATMENT REQUESTED]  [CONFIDENTIAL TREATMENT REQUESTED]
          ----------------------------------- ----------------------------------
          [CONFIDENTIAL TREATMENT             [CONFIDENTIAL TREATMENT

                                        5
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                    REQUESTED]                          REQUESTED]
          ----------------------------------- ----------------------------------
          [CONFIDENTIAL TREATMENT REQUESTED]  [CONFIDENTIAL TREATMENT REQUESTED]
          ----------------------------------- ----------------------------------
                 Cumulative Total             [CONFIDENTIAL TREATMENT REQUESTED]
          ----------------------------------- ----------------------------------

     3.2  Notwithstanding anything to the contrary set forth in Section 7.1(iii)
          of the Agreement, commencing as of the end of [CONFIDENTIAL TREATMENT
          REQUESTED] of the Commercial Phase, and at the end of each
          [CONFIDENTIAL TREATMENT REQUESTED] period thereafter, minimum payments
          payable to Nordion as a result of IDEC's Commercial Phase minimum
          purchase commitment (as such commitment may be adjusted pursuant to
          Sections 3.3, 3.4 and 3.5 below) shall take into account [CONFIDENTIAL
          TREATMENT REQUESTED] as well as [CONFIDENTIAL TREATMENT REQUESTED].

          For example, if Nordion's [CONFIDENTIAL TREATMENT REQUESTED] was
          [CONFIDENTIAL TREATMENT REQUESTED] during [CONFIDENTIAL TREATMENT
          REQUESTED], and [CONFIDENTIAL TREATMENT REQUESTED] during
          [CONFIDENTIAL TREATMENT REQUESTED], IDEC would owe Nordion
          [CONFIDENTIAL TREATMENT REQUESTED] for [CONFIDENTIAL TREATMENT
          REQUESTED], since [CONFIDENTIAL TREATMENT REQUESTED] exceeded IDEC's
          [CONFIDENTIAL TREATMENT REQUESTED] for such period. At the end of
          [CONFIDENTIAL TREATMENT REQUESTED], IDEC, however, would be required
          to pay [CONFIDENTIAL TREATMENT REQUESTED] to Nordion. [CONFIDENTIAL
          TREATMENT REQUESTED] for [CONFIDENTIAL TREATMENT REQUESTED].

          Continuing this example, if [CONFIDENTIAL TREATMENT REQUESTED]was
          [CONFIDENTIAL TREATMENT REQUESTED], IDEC would owe Nordion
          [CONFIDENTIAL TREATMENT REQUESTED] at the end of [CONFIDENTIAL
          TREATMENT REQUESTED], and [CONFIDENTIAL TREATMENT REQUESTED] --
          [CONFIDENTIAL TREATMENT REQUESTED] plus prior [CONFIDENTIAL TREATMENT
          REQUESTED].

          If IDEC were, at the end of any [CONFIDENTIAL TREATMENT REQUESTED]
          period designated above, due a refund of any over-payment of a
          [CONFIDENTIAL TREATMENT REQUESTED], IDEC shall invoice Nordion for
          such [CONFIDENTIAL TREATMENT REQUESTED] and Nordion shall forward
          payment to IDEC within thirty (30) days of the date of the invoice.

          For example, if during [CONFIDENTIAL TREATMENT REQUESTED] of the
          example described above, [CONFIDENTIAL TREATMENT

                                        6
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

          REQUESTED], IDEC would be entitled to [CONFIDENTIAL TREATMENT
          REQUESTED]. [CONFIDENTIAL TREATMENT REQUESTED] made by IDEC
          [CONFIDENTIAL TREATMENT REQUESTED] plus [CONFIDENTIAL TREATMENT
          REQUESTED] minus [CONFIDENTIAL TREATMENT REQUESTED].

     3.3  In the event Nordion has not submitted an updated DMF (or NDA, if
          required) for the KRMF Facility to the FDA on or before [CONFIDENTIAL
          TREATMENT REQUESTED]. IDEC's [CONFIDENTIAL TREATMENT REQUESTED] set
          forth in Section 3,1 above and the [CONFIDENTIAL TREATMENT REQUESTED]
          amount associated with the [CONFIDENTIAL TREATMENT REQUESTED] shall
          each be reduced by [CONFIDENTIAL TREATMENT REQUESTED] and shall
          continue to be reduced by [CONFIDENTIAL TREATMENT REQUESTED]on the
          12th day each month following [CONFIDENTIAL TREATMENT REQUESTED] until
          the updated DMF (or NDA, if required) is submitted, provided, however,
          in no event shall such reductions cause the [CONFIDENTIAL TREATMENT
          REQUESTED] and amount associated with the [CONFIDENTIAL TREATMENT
          REQUESTED] to fall below [CONFIDENTIAL TREATMENT REQUESTED].
          Attachment 1, incorporated herein by reference, sets forth the
          [CONFIDENTIAL TREATMENT REQUESTED] schedules as so reduced by
          [CONFIDENTIAL TREATMENT REQUESTED] increments.

     3.4  In the event Nordion has not established the capability to commence
          commercial supply of Isotope from the KRMF Facility by [CONFIDENTIAL
          TREATMENT REQUESTED], provided and to the extent such delay is not the
          result of the failure by IDEC to allow Nordion to cross-file the DMF
          against IDEC's BLA, IDEC's [CONFIDENTIAL TREATMENT REQUESTED] and the
          [CONFIDENTIAL TREATMENT REQUESTED] amount associated with the
          [CONFIDENTIAL TREATMENT REQUESTED], as the same may have been reduced
          pursuant to Section 3.3 above, shall each be further reduced by
          [CONFIDENTIAL TREATMENT REQUESTED] on the 12th day of each month
          following [CONFIDENTIAL TREATMENT REQUESTED] until the date by which
          Nordion is capable of commercially supplying Isotope from the KRMF
          Facility. In no event shall such reductions cause the [CONFIDENTIAL
          TREATMENT REQUESTED] and the amount associated with the [CONFIDENTIAL
          TREATMENT REQUESTED] to fall below [CONFIDENTIAL TREATMENT REQUESTED].
          Attachment 1, incorporated herein by reference, sets forth the
          [CONFIDENTIAL TREATMENT REQUESTED] schedules as so reduced by
          [CONFIDENTIAL TREATMENT REQUESTED] increments.

     3.5  If during the [CONFIDENTIAL TREATMENT REQUESTED], IDEC's demand for
          Isotope under-utilizes the capacity of [CONFIDENTIAL TREATMENT
          REQUESTED], the [CONFIDENTIAL TREATMENT REQUESTED] and the amount
          associated with the [CONFIDENTIAL TREATMENT REQUESTED] shall be
          [CONFIDENTIAL TREATMENT

                                        7
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

          REQUESTED] to the extent of [CONFIDENTIAL TREATMENT REQUESTED].
          Nordion shall have no obligation to seek out sales to third parties
          [CONFIDENTIAL TREATMENT REQUESTED].

4.   KRMF FACILITY.

     4.1  Nordion shall use commercially reasonable efforts to construct a new
          automated production suite capable of producing Isotope ("KRMF
          Facility"). It is understood and acknowledged by the parties that the
          Completion Dates and the sequence for carrying out the activities
          shall serve only as a guide. Nordion shall use commercially reasonable
          efforts to complete projects on or in advance of stated Completion
          Dates. IDEC acknowledges, however, that Nordion's ability to meet
          Completion Dates depends heavily on the ability of external vendors,
          suppliers and consultants to complete engineering, manufacture,
          deliveries and projects in a timely manner. The project schedule shall
          be as follows:

                                                           COMPLETION DATE
                                                           ---------------
                                                        (IN MONTHS FOLLOWING
                              EVENT                       EXECUTION OF THIRD
                              -----                           AMENDMENT)

          Preliminary Engineering                       [CONFIDENTIAL TREATMENT
                                                           REQUESTED]
          Major Equipment purchased                     [CONFIDENTIAL TREATMENT
                                                           REQUESTED]
          Dispensing line installation                  [CONFIDENTIAL TREATMENT
                                                           REQUESTED]
          Process Validation Completed                  [CONFIDENTIAL TREATMENT
                                                           REQUESTED]
          Submission of updated DMF (or NDA,            [CONFIDENTIAL TREATMENT
            if required)                                   REQUESTED]

          Nordion shall provide IDEC with detailed monthly progress reports as
          to the status of the project.

     4.2  The KRMF Facility shall produce Isotope for [CONFIDENTIAL TREATMENT
          REQUESTED] patient treatments or as otherwise agreed. Subject to
          Section 7.4 of the Agreement, Nordion shall produce Isotope from the
          KRMF Facility for additional patient treatment days provided
          [CONFIDENTIAL TREATMENT REQUESTED] or more vials are ordered for such
          day. Upon IDEC's request, and provided Nordion has the capacity to
          supply, Nordion shall supply Yttrium-90 from the KRMF Facility for
          other IDEC applications on the same terms and conditions of the
          Agreement subject to equitable adjustments based on dose requirements
          and such purchases shall be applied to IDEC's minimum purchase
          commitment described in Article 3 above.

                                       8
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

     4.3  The capacity of the KRMF Facility shall not be less than [CONFIDENTIAL
          TREATMENT REQUESTED], including [CONFIDENTIAL TREATMENT REQUESTED]
          required for quality control and to meet regulating requirements,
          provided, however, in no event shall the capacity of the KRMF Facility
          be less than [CONFIDENTIAL TREATMENT REQUESTED] for commercial
          shipment [CONFIDENTIAL TREATMENT REQUESTED].

     4.4  Forty five (45) days after the establishment of the capability to
          commence Commercial Supply of Isotope from the KRMF Facility, Nordion
          [CONFIDENTIAL TREATMENT REQUESTED], provided, however, this Section
          shall not reduce or relieve Nordion's supply obligation under the
          Agreement.

5.   ESCROW.

     5.1  Upon execution of this Third Amendment, IDEC shall establish an escrow
          account with Union Bank of California, N.A. ("Escrow"). Each party
          including Escrow shall execute and abide by the Escrow Agreement
          attached hereto as Attachment 2. IDEC shall, as set forth in Section
          5.2, 5.3 and 5.4 below, deposit funds into Escrow to ensure payment to
          Nordion of the minimum purchase commitment under the Agreement as well
          as IDEC's obligation to [CONFIDENTIAL TREATMENT REQUESTED] of this
          Third Amendment, or as otherwise set forth below. The cost of
          establishing and maintaining the Escrow shall be shared by IDEC and
          Nordion equally.

          IDEC shall have the right to direct Escrow to invest the funds in
          accordance with the investment guidelines attached hereto as
          Attachment 3. Subject to the terms of this Third Amendment, IDEC shall
          receive the full benefit of investment returns paid on funds in
          Escrow. Investment returns may be drawn by IDEC, in accordance with
          this Third Amendment, from Escrow on a quarterly basis.

     5.2  Upon execution of this Third Amendment, IDEC shall deposit an amount
          equal to [CONFIDENTIAL TREATMENT REQUESTED] associated with
          [CONFIDENTIAL TREATMENT REQUESTED] (as such [CONFIDENTIAL TREATMENT
          REQUESTED] and amounts are defined in Attachment 4 hereto).

     5.3  IDEC shall make additional deposits into Escrow equal to the
          [CONFIDENTIAL TREATMENT REQUESTED] associated with [CONFIDENTIAL
          TREATMENT REQUESTED] as defined in Attachment 4. For purposes of
          IDEC's obligations hereunder, Nordion and IDEC agree that the deposits
          set forth in Attachment 4 [CONFIDENTIAL TREATMENT REQUESTED]. Nordion
          shall notify IDEC in writing not less than [CONFIDENTIAL TREATMENT
          REQUESTED] prior to the anticipated commencement of the work
          associated with each [CONFIDENTIAL TREATMENT REQUESTED]. During the
          [CONFIDENTIAL TREATMENT REQUESTED] prior to each anticipated
          commencement date, IDEC shall have the right to inspect the work in
          progress to

                                        9
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

          determine if the work associated with [CONFIDENTIAL TREATMENT
          REQUESTED] is imminent and appropriate based on work completed. IDEC
          shall notify Nordion in writing not less than [CONFIDENTIAL TREATMENT
          REQUESTED] prior to each anticipated commencement date if IDEC in its
          reasonable discretion determines that the work to date is materially
          deficient or if commencement of work associated with [CONFIDENTIAL
          TREATMENT REQUESTED] is not imminent. If IDEC fails to so notify
          Nordion, IDEC shall make the requisite deposit into Escrow on or prior
          to the anticipated commencement date of the [CONFIDENTIAL TREATMENT
          REQUESTED]. Any notice by IDEC under this Section 5.3 shall include a
          detailed explanation of the reasons why the amount associated with the
          [CONFIDENTIAL TREATMENT REQUESTED]is not yet payable to Nordion
          pursuant to this Section 5.3.

          Upon receipt of such notice, if any, Nordion shall commence cure of
          any deficiency noted and shall notify IDEC upon completion. IDEC shall
          have [CONFIDENTIAL TREATMENT REQUESTED] following such notice to
          inspect the work and to determine if the work associated with the
          [CONFIDENTIAL TREATMENT REQUESTED] is imminent and appropriate. On or
          prior to expiration of such [CONFIDENTIAL TREATMENT REQUESTED] period,
          IDEC shall notify Nordion if IDEC in its reasonable discretion
          determines that the work remains materially deficient or if
          commencement of work associated with the [CONFIDENTIAL TREATMENT
          REQUESTED] is not imminent. If IDEC fails to so notify Nordion, IDEC
          shall make the requisite deposit into Escrow on or prior to the end of
          such [CONFIDENTIAL TREATMENT REQUESTED] period. Upon receipt of any
          notice under this second paragraph of Section 5.3, Nordion shall
          commence cure of any deficiency noted and reimburse IDEC for its
          reasonable travel and other out-of-pocket expenses including the
          reasonable expenses and costs of any expert retained by IDEC to review
          Nordion's work. Nordion shall notify IDEC upon completion of the work
          and the [CONFIDENTIAL TREATMENT REQUESTED] inspection period described
          above shall repeat itself until the work is completed.

          In the event IDEC fails to make a requisite deposit into the Escrow in
          accordance with this Section 5.3, Nordion shall, on [CONFIDENTIAL
          TREATMENT REQUESTED] prior written notice to IDEC and Escrow, and
          provided IDEC has not cured such failure within such [CONFIDENTIAL
          TREATMENT REQUESTED], be entitled to [CONFIDENTIAL TREATMENT
          REQUESTED].

     5.4  After the later of (i) BLA approval or (ii) the date Nordion is
          capable of commercially supplying Isotope from the KRMF Facility, IDEC
          shall then deposit into Escrow [CONFIDENTIAL TREATMENT REQUESTED] to
          ensure payment to Nordion of the [CONFIDENTIAL TREATMENT REQUESTED]
          under the Agreement. In the event IDEC fails to make the requisite
          deposit into the Escrow in accordance with this Section 5.4, Nordion

                                       10
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

          shall, upon [CONFIDENTIAL TREATMENT REQUESTED] prior written notice to
          IDEC and Escrow, and provided IDEC has not cured such failure within
          such [CONFIDENTIAL TREATMENT REQUESTED] period, be entitled to
          withdraw and retain all sums in Escrow (excluding investment returns),
          as reconciled pursuant to Section 5.6 below, and Section 2 of the
          Second Amendment shall be reinstated and Sections 2.1 -- 2.5, 3,1 --
          34, 4.1 -- 4.4, 5.1--5.13 and 7.4 of this Third Amendment shall no
          longer be applicable.

     5.5  For the purposes of Sections 5.1, 5.2, 5.3 and 54 above, the remedial
          provisions of Section 17.4 of the Agreement shall not apply to any
          breach of these Sections by IDEC.

     5.6  Notwithstanding anything to the contrary set forth in Sections 5.2,
          5.3 and 54 of this Third Amendment, IDEC and Nordion agree that the
          amount in Escrow at any time during the term of this Agreement shall
          not exceed [CONFIDENTIAL TREATMENT REQUESTED], as the same may be
          adjusted pursuant to Sections 3.3 and 3.4 above, minus cumulative
          [CONFIDENTIAL TREATMENT REQUESTED]. On the earlier of (i) the date
          IDEC would otherwise be required to deposit [CONFIDENTIAL TREATMENT
          REQUESTED] into Escrow under Section 5.4 above or [CONFIDENTIAL
          TREATMENT REQUESTED] plus (b) the amounts deposited into Escrow under
          Sections 5.2 and 5.3 exceed [CONFIDENTIAL TREATMENT REQUESTED] as the
          same may be adjusted pursuant to Sections 3.3 and 3.4, IDEC and
          Nordion shall meet to reconcile the amount in Escrow against the
          amount required to be in Escrow under this Third Amendment. Any amount
          held in Escrow which exceeds the amount required under this Third
          Amendment shall be immediately disbursed to IDEC. IDEC and Nordion
          shall also meet not less than each calendar quarter following the
          initial reconciliation to reconcile the amount in Escrow against the
          amount required in Escrow and any amount then held in Escrow which
          exceeds the amount required under this Third Amendment shall be
          immediately disbursed to IDEC.

          For example, if [CONFIDENTIAL TREATMENT REQUESTED] was [CONFIDENTIAL
          TREATMENT REQUESTED], the amount deposited in Escrow under Sections
          5.2 and 5.3 was [CONFIDENTIAL TREATMENT REQUESTED], [CONFIDENTIAL
          TREATMENT REQUESTED] was [CONFIDENTIAL TREATMENT REQUESTED, and the
          [CONFIDENTIAL TREATMENT REQUESTED] had yet to be established, then
          upon reconciliation, IDEC would be entitled to withdraw [CONFIDENTIAL
          TREATMENT REQUESTED] from Escrow. (The amount in Escrow [CONFIDENTIAL
          TREATMENT REQUESTED] exceeds the [CONFIDENTIAL TREATMENT REQUESTED]
          [CONFIDENTIAL TREATMENT REQUESTED] minus [CONFIDENTIAL TREATMENT
          REQUESTED] [CONFIDENTIAL TREATMENT REQUESTED].

          Continuing this example, if during the period until the next
          reconciliation the [CONFIDENTIAL TREATMENT REQUESTED] requirement was
          reduced

                                       11
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

          by [CONFIDENTIAL TREATMENT REQUESTED] pursuant to Section 3.3 of this
          Third Amendment and [CONFIDENTIAL TREATMENT REQUESTED] increased by
          [CONFIDENTIAL TREATMENT REQUESTED], IDEC would be entitled to withdraw
          [CONFIDENTIAL TREATMENT REQUESTED] from Escrow upon the next
          reconciliation. (The amount in Escrow [CONFIDENTIAL TREATMENT
          REQUESTED] exceeds the [CONFIDENTIAL TREATMENT REQUESTED]
          [CONFIDENTIAL TREATMENT REQUESTED] minus [CONFIDENTIAL TREATMENT
          REQUESTED] [CONFIDENTIAL TREATMENT REQUESTED].

          Further continuing this example, if the next reconciliation occurs on
          thc date IDEC would otherwise be required to deposit [CONFIDENTIAL
          TREATMENT REQUESTED] into Escrow under Section 5.4 of this Third
          Amendment and [CONFIDENTIAL TREATMENT REQUESTED] increased by
          [CONFIDENTIAL TREATMENT REQUESTED]. IDEC would not be required to
          deposit [CONFIDENTIAL TREATMENT REQUESTED] into Escrow, but rather
          would be entitled to withdraw [CONFIDENTIAL TREATMENT REQUESTED] from
          Escrow. (Thc amount in Escrow [CONFIDENTIAL TREATMENT REQUESTED]
          exceeds the [CONFIDENTIAL TREATMENT REQUESTED] [CONFIDENTIAL TREATMENT
          REQUESTED] minus [CONFIDENTIAL TREATMENT REQUESTED] [CONFIDENTIAL
          TREATMENT REQUESTED].

          Finally, if on the next reconciliation date, [CONFIDENTIAL TREATMENT
          REQUESTED] had increased by [CONFIDENTIAL TREATMENT REQUESTED], IDEC
          would be entitled to withdraw the remaining [CONFIDENTIAL TREATMENT
          REQUESTED] in Escrow and would have no further obligation to make
          deposits into Escrow. (The amount in Escrow [CONFIDENTIAL TREATMENT
          REQUESTED] exceeds the [CONFIDENTIAL TREATMENT REQUESTED]
          [CONFIDENTIAL TREATMENT REQUESTED] minus [CONFIDENTIAL TREATMENT
          REQUESTED] [CONFIDENTIAL TREATMENT REQUESTED]. Since at any time
          following this reconciliation date [CONFIDENTIAL TREATMENT REQUESTED]
          would exceed the [CONFIDENTIAL TREATMENT REQUESTED], IDEC would have
          no further obligation to make deposits into Escrow.

     5.7  In addition to Nordion's right to withdraw funds from Escrow as set
          forth in Sections 5.3 and 5.4 above, Nordion shell have the right to
          withdraw funds from Escrow as follows:

          (i)    In the event of termination of the Agreement:

                 (a)  by IDEC pursuant to Sections 2.3 or 2.4 of this Third
                 Amendment, or

                 (b)  by Nordion or IDEC pursuant to Section 17.6 of the
                 Agreement,

                                       12
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                 Nordion shall have the right to, (i) request and receive
                 payment from IDEC of those amounts set out in Section 2.3 of
                 this Third Amendment, as applicable, with respect to
                 [CONFIDENTIAL TREATMENT REQUESTED], (ii) submit requests for
                 disbursement and receive payment from Escrow, corresponding to
                 the amount determined in accordance with Sections 2.3 and 2.4
                 of this Third Amendment, as applicable, with respect to
                 [CONFIDENTIAL TREATMENT REQUESTED].

          (ii)   After the later of (i) BLA approval or (ii) the date Nordion is
                 capable of commercially supplying Isotope from the KRMF
                 Facility, Nordion shall have, on notice to IDEC and Escrow, the
                 right to submit requests for disbursements and receive payment
                 from Escrow of amounts corresponding to any [CONFIDENTIAL
                 TREATMENT REQUESTED] of Isotope pursuant to Section 3.2 of this
                 Third Amendment.

     5.8  In addition to IDEC's right to withdraw from Escrow as set forth in
          Section 5.6 above, IDEC shall have the right to withdraw investment
          returns from Escrow on a quarterly basis to the extent the principal
          has not been impaired as a result of negative investment returns.
          Requests for disbursement from Escrow of investment returns shall be
          submitted in writing to Nordion and Escrow. The request for
          disbursement shall include the determination and details of the amount
          claimed, signed by an officer of IDEC. Unless IDEC and Escrow receive
          written objection signed by an officer of Nordion within five (5)
          business days after delivery to Nordion and Escrow of IDEC's request
          for disbursement, Escrow shall immediately remit such payment to IDEC.
          In its objection, Nordion shall further stipulate those amounts in
          dispute and the details and reasons disbursement of such amounts are
          in dispute. The amounts not in dispute due and payable to IDEC shall
          be immediately disbursed to IDEC from Escrow.

     5.9  Requests for disbursement from Escrow by either party under this Third
          Amendment shall be submitted to the other party and Escrow. The
          requests for disbursement shall include the determination and details
          of the amount claimed signed by an officer of the requesting party.
          Unless the requesting party and Escrow receive written objection
          signed by an officer of the other party within five (5) business days
          after delivery to the other party and Escrow of the requesting party's
          request for disbursement, Escrow shill immediately remit such payment
          to requesting party. In its objection, the objecting party shall
          further stipulate those amounts in dispute and the details and reason
          such amounts are in dispute. The remaining amounts not in dispute due
          and payable to requesting party shall be immediately disbursed to the
          requesting party from Escrow.

     5.10 Any controversy or dispute arising out of Section 5.9 above shall be
          resolved through binding arbitration conducted by the American
          Arbitration Association under its Commercial Arbitration Rules
          ("Rules"). The arbitration shall be

                                       13
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

          conducted by a single arbitrator mutually selected by the parties from
          the National Panel of Commercial Arbitrators, or failing such
          agreement within three (3) days

                                       14
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

          of the Arbitration Demand (as defined below), as appointed by the
          American Arbitration Association under the Rules. Should the
          requesting party described in Section 5.9 disagree with the objecting
          party's objection set out above, the requesting party (except if the
          parties otherwise agree) shall send a demand of intention to arbitrate
          (the "Arbitration Demand") to the objecting party within 10 days of
          receipt by the requesting party of objecting party's notice of
          objection set out above. The objecting party shall respond to the
          Arbitration Demand within seven (7) days of receipt of such demand.
          Notwithstanding the submission of an Arbitration Demand, Escrow shall
          disburse all amounts not in dispute.

          The parties shall commence arbitration on the fifteenth (15th)
          business day after receipt by the objecting party of the Arbitration
          Demand or such date thereafter at the earliest convenience of the
          arbitrator. The arbitrator may for good cause extend any period of
          time set out in this Section 5.10. The arbitration shall be held at
          the offices of the arbitrator in the City of New York or at such other
          location as mutually agreed by the parties. The parties shall use
          reasonable efforts to complete such arbitration within one (1) day.
          The arbitrator shall render his/her decision as soon as reasonably
          possible after the conclusion of the arbitration proceedings. Nordion
          and IDEC agree that such decision shall be binding and non-appealable.
          The costs of arbitration shall be paid by the losing party with each
          party to bear its own attorney fees. The decision of the arbitrator,
          pursuant to this section, shall be limited to determination of the
          following issues, as the case may be (i) determination of whether or
          not thc requesting party's right to draw against the Escrow has been
          triggered, and (ii) the amount that may be drawn from Escrow. In
          considering the matter the arbitrator shall only be entitled to
          consider (i) notices and reports provided in accordance with this
          Third Amendment, and (ii) financial records and independent auditor
          reports (if any), with respect to Isotope sales activities, prepared
          in accordance with generally accepted accounting principles, including
          Isotope Batch manufacturing records, Isotope shipping records, Isotope
          accounts receivable and bad debts (purged of Confidential
          Information), and other such similar information or financial records
          as those referenced in this sub item (ii). For the purpose of clarity,
          IDEC acknowledges that Nordion's obligations under the Agreement are
          generally limited to the manufacture and distribution of Isotope, and
          IDEC acknowledges and agrees that under no circumstances shall IDEC
          argue or submit or the arbitrator be entitled to raise or consider
          objection to payment of amounts under the Agreement from Escrow based
          on (a) competitive market conditions encountered by Nordion or IDEC
          for the sale of Isotope or Labelled Drug, (b) Nordion's lack of
          marketing activities with respect to sale of Isotope to third parties,
          (c) the purchase price of Isotope charged by Nordion to third parties
          unless in breach of contract, (d) Force Majeure delaying or preventing
          IDEC from carrying out its obligations under the Agreement, (e) actual
          costs incurred to construct the KRMF Facility, or (f) Nordion's
          refusal to supply Isotope to customers who fail to pay invoices as
          they become due.

          The written decision of the arbitrator shall be sufficient authority
          to require and authorize release or withholding by the Escrow of funds
          in Escrow in accordance

                                       15
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

          with such decision. The arbitrator shall provide a brief written
          summary to both parties of the reasons and basis of the decision. Such
          decision shall be enforceable by any court of competent jurisdiction.

     5.11 In the event the Agreement is terminated by IDEC or Nordion pursuant
          to Section 17.5 of the Agreement (bankruptcy), the party not subject
          to the proceedings described in section 17.5 of the Agreement shall,
          on notice to the other party and Escrow, be entitled to withdraw and
          retain the amount in Escrow at such date as reconciled pursuant to
          Section 5.6 above. In the event Nordion terminates the Agreement
          pursuant to this Section 5.11, IDEC shall have a reinstatement right
          equivalent to the reinvestment right set forth in Section 2.5 of this
          Third Amendment following dismissal of such proceedings.

     5.12 In the event of termination of the Agreement for material breach by
          either party pursuant to Section 17.4 of the Agreement (material
          breach), all sums in Escrow as of the date of termination shall, in
          the event of contested termination by the other party notified to the
          terminating parry and Escrow in writing within seven (7) days of
          termination, remain in Escrow pending final determination of the
          matter by arbitration as described in Section 5.10 above. In the event
          the other party is found by the arbitrator to be in material breach of
          the Agreement, the terminating party shall be entitled to withdraw all
          sums in Escrow. If the other party is found by the arbitrator not to
          be in material breach of the Agreement, such other party shall be
          entitled to withdraw all sums in Escrow. If a termination by IDEC for
          material breach is not contested by Nordion, all sums in Escrow shall
          be disbursed to IDEC. If a termination for material breach by Nordion
          is not contested by IDEC, all sums in escrow shall be disbursed to
          Nordion. Notwithstanding anything to the contrary Set forth in this
          Section 5.12, the decision of the arbitrator pursuant to this Section
          5.12 shall not limit IDEC or Nordion, as the case may be, from
          pursuing its rights and remedies under the Agreement, including the
          right to seek damages, including the right to seek the disbursed
          funds.

     5.13 In the event of termination of the Agreement by IDEC or Nordion
          pursuant to Section 24.1 of the Agreement (Force Majeure), the
          terminating party shall, on notice to the other party, and Escrow, be
          entitled to withdraw and retain the amount in Escrow at such date as
          reconciled pursuant to Section 5.6 above. In the event Nordion
          terminates the Agreement pursuant to this Section 5.13, IDEC shall
          have a reinstatement right equivalent to the reinstatement right set
          forth in Section 2.5 of this Third Amendment following termination for
          such Force Majeure event.

6.   IDEC PROJECTIONS

     6.1  Attached to this Third Amendment as Attachment 5 is [CONFIDENTIAL
          TREATMENT REQUESTED]. The [CONFIDENTIAL TREATMENT REQUESTED].

                                       16
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

     6.2  On or about [CONFIDENTIAL TREATMENT REQUESTED] through the date
          Nordion is capable of commercially supplying Isotope from the KRMF
          Facility, IDEC shall update the [CONFIDENTIAL TREATMENT REQUESTED] and
          taking into account [CONFIDENTIAL TREATMENT REQUESTED]. IDEC and
          Nordion shall meet the [CONFIDENTIAL TREATMENT REQUESTED] to review
          the [CONFIDENTIAL TREATMENT REQUESTED].

     6.3  Without limiting Nordion's supply obligations under the Agreement,
          Nordion agrees that if [CONFIDENTIAL TREATMENT REQUESTED] indicates
          that [CONFIDENTIAL TREATMENT REQUESTED], Nordion shall adopt the
          following strategies as it selects to ensure adequate supply capacity:

STRATEGY                                 TOTAL NET VIALS/WEEK          LEAD TIME

[CONFIDENTIAL TREATMENT REQUESTED]

1.   [CONFIDENTIAL TREATMENT REQUESTED].

2.   [CONFIDENTIAL TREATMENT REQUESTED].

     6.4  Notwithstanding Section 6.3 above, if in Nordion's reasonable business
          judgment, Nordion determines that strategies 8 and 11 set forth above
          are unnecessary or premature, and IDEC requires the implementation of
          either such strategy, IDEC shall pay Nordion an amount equal to
          [CONFIDENTIAL TREATMENT REQUESTED] of the reasonable out-of-pocket
          labor and material costs associated with strategy 8, or [CONFIDENTIAL
          TREATMENT REQUESTED] of the reasonable out-of-pocket costs (and
          Nordion labour costs at the foregoing rate) associated with strategy
          11, if less than, an average of [CONFIDENTIAL TREATMENT REQUESTED] are
          required and purchased to meet Isotope demand from the implementation
          of such strategies during the period the [CONFIDENTIAL TREATMENT
          REQUESTED] excess demand.

     6.5  Nordion agrees it shall promptly disclose to IDEC any information it
          acquires that would be reasonably indicative of a potential Force
          Majeure event, including without limitation, a labor disruption or
          strike. In the event of a Force Majeure event, Nordion shall exercise
          commercially reasonable efforts to eliminate, cure or overcome such
          event, which efforts shall include, without limitation, the

                                       17
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

          strategies described in Section 6.3 above and the lawful deployment of
          management if possible, to operate the Isotope facilities.

7.   OTHER MATTERS

     7.1  In the event IDEC is entitled under the Agreement to seek supply of
          Isotope from a third party, the minimum purchase commitment described
          in Section 3.1 of this Third Amendment shall be reduced
          proportionately.

     7.2  During the period of supply from both the original and New Facility,
          Nordion may be required to produce Isotope in up to [CONFIDENTIAL
          TREATMENT REQUESTED]. During thc period of such increased production
          from the original or New Facility, the reference in Section 8.4 (c)
          (i) of the Agreement to [CONFIDENTIAL TREATMENT REQUESTED] shall be
          amended to provide for [CONFIDENTIAL TREATMENT REQUESTED]. After
          Nordion has submitted and updated the DMF for and is supplying Isotope
          from the KRMF Facility, the reference in Section 8.4 (c) (i) of the
          Agreement shall revert back to [CONFIDENTIAL TREATMENT REQUESTED]."

     7.3  The references in Section 17.6 of the Agreement to [CONFIDENTIAL
          TREATMENT REQUESTED] arc hereby amended to refer to [CONFIDENTIAL
          TREATMENT REQUESTED].

     7.4  Section 17.2 of the Agreement is hereby deleted and replaced with the
          following:

          17.2   Extension

                 IDEC may extend the term of the Agreement by an additional
                 [CONFIDENTIAL TREATMENT REQUESTED] after the expiration of the
                 Initial Term by providing written notice to Nordion of its
                 election to extend [CONFIDENTIAL TREATMENT REQUESTED].
                 Notwithstanding the foregoing, [CONFIDENTIAL TREATMENT
                 REQUESTED].

8.   NO FURTHER MODIFICATIONS

     8.1  Except as set forth in this Third Amendment all of the terms and
          conditions of the Agreement shall remain unmodified and in full force
          and effect. Effective as of the date hereof, all references to the
          Agreement shall refer to the Agreement as amended by this Third
          Amendment.

     IN WITNESS WHEREOF, the parties hereto have executed this Third Amendment
as of the date first above written.

MDS (CANADA) INC.                   IDEC PHARMACEUTICALS CORPORATION

By: /s/ Dr. Iain Trevena            By: /s/ Mark Wiggins

                                       18
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

Its: Senior Vice President          Its: Vice President, Marketing and Business
     Nuclear Medicine                    Development

                                       19
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                ATTACHMENT 1: [CONFIDENTIAL TREATMENT REQUESTED]

                [CONFIDENTIAL TREATMENT REQUESTED]

                                       20
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                         ATTACHMENT 2: ESCROW AGREEMENT

This Escrow Agreement (`Agreement") is made and entered into as of ________ by
and between IDEC Pharmaceuticals Corporation ("IDEC"), MDS (Canada) Inc., MDS
Nordion division, successor to MDS Nordion Inc. ("Nordion"), and Union Bank of
California, N.A. ("Escrow Agent") as follows;

1.0  ESCROW INSTRUCTIONS

1.1  IDEC has agreed with Nordion to deposit and maintain certain funds in
     escrow.

1.2  The Escrow Agent agrees to accept said funds for deposit and to establish
     and maintain a separate account for such funds. Within two (2) business
     days following receipt of a deposit by IDEC, Escrow Agent shall notify
     Nordion thereof in writing.

1.3  Subject to section 1.4 of this Agreement, upon receipt by Escrow Agent of a
     written request for disbursement of funds from escrow from either party
     signed by an officer of the requesting party, Escrow Agent shall
     immediately remit such funds to the requesting party. Thc request for
     disbursement shall set forth the determination of the amount to be paid,
     the payee and payee's address or wire instructions.

1.4  If the requesting party and Escrow Agent receive written objection signed
     by an officer of the other party within five (5) days after delivery to the
     other party and Escrow Agent of the requesting party's request for
     disbursement, escrow Agent shall, withhold disbursement of the funds and
     remain in possession of such funds pending resolution by Nordion and IDEC
     of the objection by mutual agreement or by arbitration. In such written
     objection, the objecting party shall stipulate those amounts in dispute,
     the details and reason such amounts are in dispute and those amounts not in
     dispute. If no such objection is received, the Escrow Agent shall
     immediately disburse those funds in escrow as requested by the requesting
     party or, as the case may be, those amounts that are not in dispute. Escrow
     Agent will accept facsimile signatures with original signatures to follow.

1.5  The written request of a requesting parry in accordance with this
     Agreement, mutual written agreement of IDEC and Nordion or written decision
     of the arbitrator shall be sufficient authority to require and authorize
     release or withholding by the Escrow Agent of funds in escrow.

1.6  Escrow Agent shall provide monthly account statements by mail to IDEC and
     Nordion setting out the principal amounts deposited into escrow, investment
     returns accrued and withdrawn, the extent to which the principal has been
     impaired as a result of negative investment returns and any other
     withdrawal or disbursement of funds in escrow during the term of the
     escrow. Escrow Agent shall provide prompt notice to Nordion, with a copy to
     IDEC, if the investment has been impaired as a result of negative
     investment returns.

1.7  The escrow shall only bc terminated upon joint written instruction from the
     parties to this escrow or the disbursement of all funds in escrow.

                                       21
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

1.8  Escrow Agent shall invest the funds deposited in escrow pursuant to written
     instructions from IDEC, provided such instructions are in accordance with
     the investment guidelines described in the guidelines attached hereto and
     incorporated herein by reference. IDEC shall fail to provide such
     instructions, Escrow Agent shall invest funds in the Provident Cash
     Management Shares T-Fund and it is understood that Escrow Agent may render
     administrative services and receive fees from thc distributor of such Fund.
     Upon receipt of notice of request for disbursement from escrow, in
     accordance with this Agreement Escrow Agent agrees to liquidate the
     investment to the extent required and to disburse the proceeds to the
     requesting party.

2.0  RIGHTS OF ESCROW AGENT

2.1  The Escrow Agent shall have no duties or responsibilities except those
     expressly set forth herein.

2.2  No person, firm or corporation will be recognized by the Escrow Agent as a
     successor or Assignee of this Agreement until acknowledgment by Nordion and
     IDEC of such successor or assignment is received by Escrow Agent and
     written evidence be presented to the Escrow Agent, which evidence is
     satisfactory to the Escrow Agent of such succession or assignment.

2.3  The Escrow Agent shall not be responsible for confirming the identity,
     authority or rights of any person, firm or corporation executing or
     delivering or purporting to deliver or execute this Escrow Agreement.

2.4  The Escrow Agent may rely upon any instrument in writing believed by it to
     be genuine and sufficient and properly presented and shall not be liable or
     responsible for any action taken or omitted in accordance with the
     provisions thereof.

2.5  The Escrow Agent shall not be liable or responsible for any act it may do
     or omit to do except for its negligence or willful misconduct. The Escrow
     Agent may consult with an attorney and be fully protected with respect to
     any action taken or omitted by it in good faith or on advice of counsel.

2.6  In the event any property held by the Escrow Agent hereunder shall be
     attached, garnished or levied upon under any court order or if the delivery
     of such property shall be stayed or enjoined by any court order, or if any
     court order, judgement or decree shall be made or entered affecting such
     property or affecting any act by the Escrow Agent, the Escrow Agent shall
     obey and comply with all writs, orders, judgments or decrees so entered or
     issued, notwithstanding any provisions of this Escrow Agreement to the
     contrary. If the Escrow Agent obeys and complies with any such writs or
     decrees, it shall nor be liable to any other parties hereto or to such
     other person, firm or entity by reason of such compliance, notwithstanding
     that such writs, orders or decree may be subsequently reversed, modified,
     annulled, set aside or vacated.

2.7  IDEC and Nordion shall each pay one-half (1/2) of Escrow Agent's reasonable
     compensation and shall reimburse the Escrow Agent for all reasonable
     expenses incurred by the Escrow Agent in connection with the duties and
     compliance in good faith with the

                                       22
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

     terms and conditions of this Escrow Agreement. IDEC and Nordion
     respectively shall indemnify and hold the Escrow Agent harmless against any
     and all losses, claims, liabilities, costs, payments and including
     reasonable legal fees for counsel who may be selected by the Escrow Agent,
     which may be imposed upon or incurred by Escrow Agent hereunder as a result
     of the respective acts or omissions of IDEC or Nordion, as the case may be,
     Escrow Agent's fee schedule is attached hereto as Exhibit A. Escrow Agent
     may withdraw compensation and expenses from account income in the event
     payment is not received by Escrow Agent within thirty (30) days of the date
     of invoice.

2.8  The Escrow Agent makes no representation as to the validity, value,
     genuineness or the collectibility of any security or other document or
     instrument held by or delivered to it.

     Escrow Agent may resign on thirty (30) days' written notice to IDEC and
     Nordion. IDEC and Nordion may remove Escrow Agent on thirty (30) days'
     written notice to all parties hereunder. Upon receipt of such notice, IDEC
     and Nordion shall appoint a successor escrow agent in writing delivered to
     Escrow Agent. Thereupon, Escrow Agent shall deliver all assets in its
     custody to such successor escrow agent and all responsibility of Escrow
     Agent under this Agreement shall terminate; provided, however, Escrow
     Agent's obligations under this Agreement shall not terminate until delivery
     of the assets to the successor Escrow Agent. If the parties fail to appoint
     a successor escrow agent, within five (5) days of expiry of the
     aforementioned thirty (30) day notice period, the Escrow Agent shall
     deliver all assets in escrow in its custody to a court of competent
     jurisdiction as IDEC and Nordion shall instruct in writing or, in the
     absence of such joint instruction, to an escrow agent appointed by a court
     of competent jurisdiction as petitioned by any party to this Agreement.

     Escrow Agent may consult with independent legal counsel in the event of any
     dispute or question as to the interpretation of any of the provisions
     hereof or its duties hereunder and it shall incur no liability and shall be
     fully protected in acting in accordance with the opinion and instructions
     of such counsel. Escrow Agent shall notify IDEC and Nordion in writing when
     it intends to consult with such independent legal counsel and the
     anticipated cost. Escrow Agent shall have the right to file legal
     proceedings, including an interpleader, to determine the proper disposition
     of assets hereunder, all costs thereof constituting an expense of
     administration of this Agreement.

     The duties and responsibilities of Escrow Agent shall be limited to those
     expressly set forth in this Escrow Agreement; provided, however, that, with
     Escrow Agent's written consent, the duties and responsibilities in this
     Escrow Agreement may bc amended at any time or times by an instrument in
     writing signed by the parties. With the exception of this Agreement Escrow
     Agent is not responsible for, or chargeable with knowledge of, any terms or
     provisions contained in either the underlying agreement referred to in this
     Agreement or any other separate agreements and understandings between the
     parties. Thc Escrow Agent shall not be liable for the accuracy of any
     calculations or the sufficiency of any funds for any purpose. The Escrow
     Agent shall not have any liability under this Escrow Agreement except to
     the extent of its own gross negligence or willful misconduct. In no event
     shall the escrow Agent be liable for any special, indirect or consequential
     damages.

                                       23
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

     Escrow Agent is authorized, in its sole discretion, to disregard any and
     all notices or instructions given by IDEC and Nordion or by any other
     person, firm or corporation, except such notices or instructions as are
     specifically provided for herein.

3.0  MISCELLANEOUS

3.1  All communications, notices, requests, consents or demands given or
     required under this Agreement shall be in writing and shall be deemed to
     have been duly given when delivered to, sent by facsimile with acknowledged
     receipt or recognized courier service with acknowledged receipt, or five
     days after being mailed by prepaid registered or certified mail addressed
     to, the party for whom intended, as follows, or to such other address as
     may be furnished by such party by notice in the manner provided herein:

     IDEC:            3030 Callan Road
                      San Diego, CA  92121
                      Attn: Senior Vice President and Chief Financial Officer
                      Fax: (858) 431-8892

     Nordion:         447 March Road
                      Ottawa, Ontario
                      K2K1X8
                      Attn: Vice President and Chief Financial Officer
                      Fax: (613) 592-5302

     Escrow Agent:    Union Bank of California, N.A.
                      120 S.  San Pedro Street, 4th Floor
                      Los Angeles, CA  90012
                      Attn: Corporate Trust Department
                      Fax: (213) 972-5694

3.2  The name, title, and specimen signature of each individual authorized to
     provide notices hereunder (including requests for disbursement) is attached
     as Exhibit B hereto and IDEC and Nordion represent and warrant that each
     individual so listed is authorized to give such notice- IDEC and Nordion
     may, from time to time, as each respectively deems appropriate, add such
     persons to Exhibit B, who are authorized to provide notices hereunder.

3.3  This Agreement shall be binding upon, enforceable against and inure to the
     benefit of, the parties hereto and their respective heirs, administrators,
     executors, personal representatives, successors and permitted assigns, and
     nothing herein is intended to confer any right, remedy or benefit upon any
     other person. This Agreement may not be assigned by any party hereto except
     with the prior written consent of all the other parties, which consent
     shall not be unreasonably withheld.

     If any provision of this Agreement is held to be invalid or unenforceable
     by a court of competent jurisdiction, this Agreement shall be interpreted
     and enforceable as if such provision were severed or limited, but only to
     the extent necessary to render such provision and this Agreement
     enforceable.

                                       24
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

3.4  This Agreement shall in all respects be governed by and construed in
     accordance with the laws of the State of California applicable to
     agreements made and fully to be performed in such state, without giving
     effect to conflicts of law principles.

3.5  This Agreement may be executed in multiple counterparts, each of which
     shall be deemed an original, but all of which together shall constitute one
     and the same instrument.

     IN WITNESS WHEREOF, the parties hereto have executed this Escrow Agreement
or this Escrow Agreement to be duly executed by their duly authorized
representatives, as of the date first written below:

ESCROW AGENT:              Union Bank of California, N.A.

     By:
                           --------------------------------------------
     Executed this date, November _____, 2001
IDEC:

     By:
                           --------------------------------------------
     Executed this date, November _____, 2001

NORDION:

     By:
                           --------------------------------------------
     Executed this date, November _____, 2001

                                       25
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                                    EXHIBIT A

                                  FEE SCHEDULE

                         UNION BANK OF CALIFORNIA, N.A.
                            CORPORATE TRUST SERVICES

                                SCHEDULE OF FEES
                                       FOR
                              ESCROW AGENT SERVICES

                                ESCROW AGREEMENT
                                      AMONG
                        IDEC PHARMACEUTICALS CORPORATION,
                     MDS (CANADA) INC., MDS NORDION DIVISION
                                       AND
                          UNION BANK OF CALIFORNIA, NA.
--------------------------------------------------------------------------------
<Table>

<S>                                                                    <C>
ACCEPTANCE AND SET-UP FEE:                                             [CONFIDENTIAL TREATMENT
(DUE AND PAYABLE ON THE CLOSING DATE)                                               REQUESTED]

ANNUAL ESCROW ADMINISTRATION                                           [CONFIDENTIAL TREATMENT
(FIRST YEAR'S FEE IS DUE AND PAYABLE IN ADVANCE ON THE CLOSING DATE)                REQUESTED]

LEGAL COUNSEL FEE:                                                                   NO CHARGE
(USE OF UNION BANK IN-HOUSE LEGAL COUNSEL)

TRANSACTIONAL CHARGES:                                                 [CONFIDENTIAL TREATMENT
         DISBURSEMENTS/WIRES (EACH):                                                REQUESTED]
         INVESTMENTS (PER SALE/PURCHASE/TRANSFER):

OUT-OF-POCKET EXPENSES:                                                            AS INVOICED

ACCEPTED BY:________________________________                           DATE:___________________

FEES SUBJECT TO ACCEPTANCE AND REVIEW BY UNION BANK OF CALIFORNIA, N.A.  OF ALL DOCUMENTS
PERTAINING TO THIS ISSUE.
</Table>

                                       26
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                                    EXHIBIT B

IDEC:

Name:                               Signature

----------------------------------------------------------------------

Name:                               Signature

----------------------------------------------------------------------

NORDION:

Name:                               Signature

----------------------------------------------------------------------

Name:                               Signature

----------------------------------------------------------------------

                                       27
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                        IDEC PHARMACEUTICALS CORPORATION
                          SHORT-TERM INVESTMENT POLICY

                              INVESTMENT OBJECTIVES

     A.   [CONFIDENTIAL TREATMENT REQUESTED]

INVESTMENTS SHALL CONSIST OF THE FOLLOWING TYPES OF SECURITIES:

                       [CONFIDENTIAL TREATMENT REQUESTED]

          [CONFIDENTIAL TREATMENT REQUESTED]

                                       28
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                 ATTACHMENT 3: IDEC PHARMACEUTICALS CORPORATION
                          SHORT-TERM INVESTMENT POLICY

                              INVESTMENT OBJECTIVES

          [CONFIDENTIAL TREATMENT REQUESTED]

                                       29
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                ATTACHMENT 4: [CONFIDENTIAL TREATMENT REQUESTED]

-------------------------------------------------------------------------------

-------------------------------------------------------------------------------

                       [CONFIDENTIAL TREATMENT REQUESTED]

-------------------------------------------------------------------------------

                                       30
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                                  ATTACHMENT 5:

          [CONFIDENTIAL TREATMENT REQUESTED]

                                       31

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}]]